Who is sponsoring NCT04381923?

NCT04381923 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT04381923?

Interventions in NCT04381923: Helmet Continuous Positive Airway Pressure (CPAP), High Flow Nasal Oxygen (HFNO).

What condition does NCT04381923 study?

NCT04381923 studies Severe Acute Respiratory Syndrome Coronavirus 2, Hypoxemic Respiratory Failure, Pneumonia, Viral, COVID.

Is NCT04381923 still recruiting?

NCT04381923 is currently withdrawn. Last updated 5 April 2022.

Last reviewed 2022-04-05 · How we verify

NCT04381923: COVIDNOCHE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia

Withdrawn NA Last updated 5 April 2022

What this trial tests

NA trial testing Helmet Continuous Positive Airway Pressure (CPAP) in Severe Acute Respiratory Syndrome Coronavirus 2. Withdrawn.

Timeline

15 November 2021

Primary endpoint
15 November 2022

15 December 2022

Quick facts

Lead sponsor	University of Pennsylvania
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	supportive care
Start date	15 November 2021
Primary completion	15 November 2022
Estimated completion	15 December 2022
Sites	1 location across United States

Drugs / interventions tested

Helmet Continuous Positive Airway Pressure (CPAP)
High Flow Nasal Oxygen (HFNO)

Conditions studied

Severe Acute Respiratory Syndrome Coronavirus 2 — all drugs for Severe Acute Respiratory Syndrome Coronavirus 2 →
Hypoxemic Respiratory Failure — all drugs for Hypoxemic Respiratory Failure →
Pneumonia, Viral — all drugs for Pneumonia, Viral →
COVID — all drugs for COVID →

Sponsor

University of Pennsylvania

Who can join

18 and older, any sex, with Severe Acute Respiratory Syndrome Coronavirus 2 or Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the COVIDNOCHE trial (HFNO versus CPAP Helmet Evaluation in COVID-19 Pneumonia) is to evaluate the comparative effectiveness of standard care non-invasive respiratory support (helmet CPAP versus HFNO) for acute hypoxemic respiratory failure from COVID-19 pneumonia on ventilator-free days (primary outcome) and other clinical outcomes measured up to 90 days.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).
Bassetti M, Giacobbe DR, Bruzzi P, Barisione E, et al · · 2021 · cited 29× · PMID 34328629 · DOI 10.1007/s40121-021-00487-7
COVID-19 Critical Illness: A Data-Driven Review.
Ginestra JC, Mitchell OJL, Anesi GL, Christie JD. · · 2022 · cited 24× · PMID 34520220 · DOI 10.1146/annurev-med-042420-110629
Early Clinical Experience in Using Helmet Continuous Positive Airway Pressure and High-Flow Nasal Cannula in Overweight and Obese Patients With Acute Hypoxemic Respiratory Failure From Coronavirus Disease 2019.
Gaulton TG, Bellani G, Foti G, Frazer MJ, et al · · 2020 · cited 16× · PMID 32984836 · DOI 10.1097/cce.0000000000000216
High-Flow Nasal Oxygen and Noninvasive Ventilation for COVID-19.
Al-Dorzi HM, Kress J, Arabi YM. · · 2022 · cited 4× · PMID 35667746 · DOI 10.1016/j.ccc.2022.01.006
Helmet Non-Invasive Ventilation for COVID-19 Patients (Helmet-COVID): study protocol for a multicentre randomised controlled trial.
Arabi YM, Tlayjeh H, Aldekhyl S, Al-Dorzi HM, et al · · 2021 · cited 4× · PMID 34446500 · DOI 10.1136/bmjopen-2021-052169
Noninvasive ventilation strategies for patients with severe or critical COVID-19: A rapid review of clinical outcomes
Kelly SE, Wells GA. · · 2022 · DOI 10.1101/2022.05.25.22275586
Helmet noninvasive ventilation for COVID-19 patients “Helmet-COVID”: study protocol for a multicenter randomized controlled trial
Arabi Y, Tlayjeh H, Aldekhyl S, Al-Dorzi HM, et al · · 2021 · DOI 10.1101/2021.08.04.21260420

Verify or expand the search:

Other recruiting trials for Severe Acute Respiratory Syndrome Coronavirus 2

Currently open trials in the same condition.

NCT05543616 — A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children · Phase 3 · active not recruiting
NCT04987528 — Pulmonary Fibrosis During Severe COVID-19 Pneumonia · active not recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04381923 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 5 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04381923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing